Last Updated : March 18, 2024
Details
FilesGeneric Name:
treosulfan
Project Status:
Active
Therapeutic Area:
Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)
Manufacturer:
Medexus Pharmaceuticals Inc.
Call for patient/clinician input open:
Brand Name:
Trecondyv
Project Line:
Reimbursement Review
Project Number:
PC0324-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
In combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | 02-Jun-23 |
---|---|
Call for patient/clinician input closed | 28-Jul-23 |
Clarification: - Patient input submission received from The Leukemia & Lymphoma Society of Canada (LLSC) | |
Submission received | 14-Jul-23 |
Submission accepted | 08-Aug-23 |
Clarification: - Submission was not accepted for review on 28 Jul 23 | |
Review initiated | 09-Aug-23 |
Draft CADTH review report(s) provided to sponsor for comment | 09-Nov-23 |
Deadline for sponsors comments | 21-Nov-23 |
CADTH review report(s) and responses to comments provided to sponsor | 21-Dec-23 |
Expert committee meeting (initial) | 10-Jan-24 |
Draft recommendation issued to sponsor | 22-Jan-24 |
Draft recommendation posted for stakeholder feedback | 01-Feb-24 |
End of feedback period | 15-Feb-24 |
Final recommendation issued to sponsor and drug plans | 28-Feb-24 |
Final recommendation posted | 18-Mar-24 |
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 13-Mar-24 |
CADTH review report(s) posted | - |
Files
Last Updated : March 18, 2024